Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro

Clinical Oral Investigations

Volumn 15, Issue 1, 2011, Pages 105-111

  Ziebart, Thomas ^a   Pabst, Andreas ^a   Klein, Marcus Oliver ^a   Kämmerer, Peer ^a   Gauss, Leonie ^a   Brüllmann, Dan ^a   Al Nawas, Bilal ^a   Walter, Christian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Bisphosphonate; Bisphosphonate associated osteonecrosis of the jaws; EPC; HUVEC; Vasculogenesis

Indexed keywords

EID: 78751648671     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-009-0365-2     Document Type: Article

References (34)

1. Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5(10): 475-482.
2. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61(9): 1115-1117.
3. Walter C, Grotz KA, Kunkel M et al (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2): 197-202.
4. Ruggiero SL, Dodson TB, Assael LA et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(5 Suppl): 2-12.
5. Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6): 826-836.
6. Boonyapakorn T, Schirmer I, Reichart PA et al (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44(9): 857-869.
7. Walter C, Al-Nawas B, Grotz KA et al (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5): 1066-1072.
8. Abu-Id MH, Warnke PH, Gottschalk J et al (2008) "Bis-phossy jaws"-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36(2): 95-103.
9. Lam DK, Sandor GK, Holmes HI et al (2007) A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 73(5): 417-422.
10. Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66(5): 839-847.
11. Simon MJ, Niehoff P, Kimmig B et al. (2009) Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig. In press.
12. Gerber HP, Ferrara N (2000) Angiogenesis and bone growth. Trends Cardiovasc Med 10(5): 223-228.
13. Asahara T, Masuda H, Takahashi T et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85(3): 221-228.
14. Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302): 964-967.
15. Ziebart T, Yoon CH, Trepels T et al (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 103(11): 1327-1334.
16. Urbich C, Heeschen C, Aicher A et al (2005) Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11(2): 206-213.
17. Allegra A, Oteri G, Nastro E et al (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25(4): 164-169.
18. Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8(5): 1080-1084.
19. Hasmim M, Bieler G, Ruegg C (2007) Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5(1): 166-173.
20. Mashiba T, Hirano T, Turner CH et al (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4): 613-620.
21. Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl): 61-70.
22. Conway EM, Collen D, Carmeliet P (2001) Molecular mechanisms of blood vessel growth. Cardiovasc Res 49(3): 507-521.
23. Aicher A, Kollet O, Heeschen C et al (2008) The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103(8): 796-803.
24. Soltau J, Zirrgiebel U, Esser N et al (2008) Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 28(2A): 933-941.
25. Santini D, Vespasiani Gentilucci U, Vincenzi B et al (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14(10): 1468-1476.
26. Wood J, Bonjean K, Ruetz S et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3): 1055-1061.
27. Bezzi M, Hasmim M, Bieler G et al (2003) Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278(44): 43603-43614.
28. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62(22): 6538-6544.
29. Okamoto T, Yamagishi S, Inagaki Y et al (2002) Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 297(2): 419-424.
30. Yamada J, Tsuno NH, Kitayama J et al (2009) Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 151(1): 115-120.
31. Frith JC, Monkkonen J, Blackburn GM et al (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12(9): 1358-1367.
32. Nogawa M, Yuasa T, Kimura S et al (2005) Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15(1): 1-9.
33. Bifulco M (2005) Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci 77(14): 1740-1749.
34. Crick DC, Andres DA, Waechter CJ (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237(3): 483-487.